RMC-7977 is the latest of small molecule drugs coming out of Revolution Medicine targeting KRAS mutations. There has only been pre-clinical results from testing in mouse models. The results were published in the Journal Nature last week and the senior author of the paper was Ken Olive PhD of Columbia University. He is an extremely talented pancreatic cancer researcher that was mentored by David Tuveson, MD-PhD who is the director of Cold Spring Harbor Cancer Research Labs. I’ve attended a couple of lectures given by Dr. Olive. While working under Dr. Tuveson, he developed the mouse model now used in pre-clinical pancreatic cancer research.
The next step is in Revolution Medicine working in partnership with academic medical centers to initiate a phase I clinical trial. This won’t happen overnight as there is a lot of legwork that goes into the planning, development and initiation of human clinical trials. Columbia Presbyterian may likely be one of the first sites for conducting a trial of RMC-7977.